Research programme: chimeric antigen receptor tumour cell therapy - NantKwest/Sorrento TherapeuticsAlternative Names: CAR-TNK™; CD123-CAR.TNK™; CD123.TNK™; Chimeric antigen receptor tumor - attacking Neukoplast®; PD-L1-CAR.TNK™; PD-L1.TNK™; PSMA-CAR.TNK™; PSMA.TNK™; ROR1-CAR.TNK™; ROR1.TNK™
Latest Information Update: 19 Sep 2015
At a glance
- Originator Conkwest; Sorrento Therapeutics
- Developer NantKwest; Sorrento Therapeutics
- Class Cell therapies
- Mechanism of Action Immunomodulators; Natural killer cell modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
- Research Prostate cancer